Csl Ltd has released a press release.
CSL Statutory Accounts for FY2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
- Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
- U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
- England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
- CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
Later from CSL
- CSL Results Presentation
- CSL FY25 Results and Major Strategic Initiatives
- CSL partners on new coagulation treatment
- VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
- CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Follow CSL into a list and get an email when it puts out news.
Follow CSL